Lenalidomide in Multiple Myeloma-a Practice Guideline

Overview

Journal Curr Oncol

Publisher MDPI

Specialty Oncology

Date 2013 Apr 6

PMID 23559881

Citations 9

Authors

C Chen

F Baldassarre

S Kanjeekal

J Herst

L Hicks

M Cheung

Affiliations

Soon will be listed here.

Abstract

Background: Promising new drugs such as lenalidomide, an immunomodulatory agent, are available for the treatment of multiple myeloma. We describe the process of creating a provincial guideline for the use of lenalidomide, alone or in combination with other drugs, in relapsed, refractory, or newly diagnosed disease (including smoldering and symptomatic patients, and candidates and non-candidates for transplant) and in maintenance treatment (after transplant or non-transplant therapy); and for strategies to manage lenalidomide-related toxicities.

Methods: Outcomes of interest included overall survival, event-free survival, progression-free survival, time to progression, time to next treatment, response rate, and incidence of serious toxicity. The medline, embase, and Cochrane Library databases, as well as meeting abstracts and the Web sites of relevant organizations, were systematically searched for relevant literature.

Results: Recommendations were developed using the evidence from published studies and the clinical expertise of the working group and of the Cancer Care Ontario Hematology Disease Site Group.

Conclusions: Lenalidomide in combination with dexamethasone can be recommended for both previously untreated and treated patients with multiple myeloma. Guidelines for the management of cytopenias, venous thromboembolism, and second primary malignancies are discussed.

Citing Articles

Lenalidomide plus Dexamethasone Combination as First-Line Oral Therapy of Multiple Myeloma Patients: A Unicentric Real-Life Study.

Del Fabro V, Di Giorgio M, Leotta V, Duminuco A, Bellofiore C, Markovic U Cancers (Basel). 2023; 15(16).

PMID: 37627065 PMC: 10452433. DOI: 10.3390/cancers15164036.

Comparative Efficacy of Teclistamab Versus Current Treatments in Real-World Clinical Practice in the Prospective LocoMMotion Study in Patients with Triple-Class-Exposed Relapsed and/or Refractory Multiple Myeloma.

Moreau P, van de Donk N, Delforge M, Einsele H, De Stefano V, Perrot A Adv Ther. 2023; 40(5):2412-2425.

PMID: 36961654 PMC: 10129954. DOI: 10.1007/s12325-023-02480-7.

Expression and Importance of TMED2 in Multiple Myeloma Cells.

Ge X, Jiang W, Jiang Y, Lv X, Liu X, Wang X Cancer Manag Res. 2020; 12:12895-12903.

PMID: 33364837 PMC: 7751311. DOI: 10.2147/CMAR.S278570.

MCLENA-1: A Phase II Clinical Trial for the Assessment of Safety, Tolerability, and Efficacy of Lenalidomide in Patients with Mild Cognitive Impairment Due to Alzheimer's Disease.

Decourt B, Wilson J, Ritter A, Dardis C, DiFilippo F, Zhuang X Open Access J Clin Trials. 2020; 12:1-13.

PMID: 32123490 PMC: 7051033. DOI: 10.2147/oajct.s221914.

Determining therapeutic susceptibility in multiple myeloma by single-cell mass accumulation.

Cetin A, Stevens M, Calistri N, Fulciniti M, Olcum S, Kimmerling R Nat Commun. 2017; 8(1):1613.

PMID: 29151572 PMC: 5694762. DOI: 10.1038/s41467-017-01593-2.

References

Lyman G, Khorana A, Falanga A, Clarke-Pearson D, Flowers C, Jahanzeb M . American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol. 2007; 25(34):5490-505. DOI: 10.1200/JCO.2007.14.1283. View

Zangari M, Tricot G, Polavaram L, Zhan F, Finlayson A, Knight R . Survival effect of venous thromboembolism in patients with multiple myeloma treated with lenalidomide and high-dose dexamethasone. J Clin Oncol. 2009; 28(1):132-5. DOI: 10.1200/JCO.2009.23.0169. View

Dimopoulos M, Chen C, Spencer A, Niesvizky R, Attal M, Stadtmauer E . Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma. Leukemia. 2009; 23(11):2147-52. DOI: 10.1038/leu.2009.147. View

Attal M, Lauwers-Cances V, Marit G, Caillot D, Moreau P, Facon T . Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012; 366(19):1782-91. DOI: 10.1056/NEJMoa1114138. View

Hazarika M, Rock E, Williams G, Dagher R, Sridhara R, Booth B . Lenalidomide in combination with dexamethasone for the treatment of multiple myeloma after one prior therapy. Oncologist. 2008; 13(10):1120-7. DOI: 10.1634/theoncologist.2008-0077. View

San-Miguel J, Dimopoulos M, Stadtmauer E, Rajkumar S, Siegel D, Bravo M . Effects of lenalidomide and dexamethasone treatment duration on survival in patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone. Clin Lymphoma Myeloma Leuk. 2011; 11(1):38-43. DOI: 10.3816/CLML.2010.n.120. View

Jacobus S, Kumar S, Uno H, Van Wier S, Ahmann G, Henderson K . Impact of high-risk classification by FISH: an eastern cooperative oncology group (ECOG) study E4A03. Br J Haematol. 2011; 155(3):340-8. PMC: 3192237. DOI: 10.1111/j.1365-2141.2011.08849.x. View

Richardson P, Blood E, Mitsiades C, Jagannath S, Zeldenrust S, Alsina M . A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood. 2006; 108(10):3458-64. PMC: 1895441. DOI: 10.1182/blood-2006-04-015909. View

Dimopoulos M, Alegre A, Stadtmauer E, Goldschmidt H, Zonder J, de Castro C . The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function. Cancer. 2010; 116(16):3807-14. PMC: 2970911. DOI: 10.1002/cncr.25139. View

10.

Zonder J, Crowley J, Hussein M, Bolejack V, Moore Sr D, Whittenberger B . Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232). Blood. 2010; 116(26):5838-41. PMC: 3031379. DOI: 10.1182/blood-2010-08-303487. View

11.

Carrier M, Le Gal G, Tay J, Wu C, Lee A . Rates of venous thromboembolism in multiple myeloma patients undergoing immunomodulatory therapy with thalidomide or lenalidomide: a systematic review and meta-analysis. J Thromb Haemost. 2011; 9(4):653-63. DOI: 10.1111/j.1538-7836.2011.04215.x. View

12.

McCarthy P, Owzar K, Hofmeister C, Hurd D, Hassoun H, Richardson P . Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012; 366(19):1770-81. PMC: 3744390. DOI: 10.1056/NEJMoa1114083. View

13.

Rajkumar S, Jacobus S, Callander N, Fonseca R, Vesole D, Williams M . Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol. 2009; 11(1):29-37. PMC: 3042271. DOI: 10.1016/S1470-2045(09)70284-0. View

14.

. Guideline summary: use of epoetin and darbepoetin in patients with cancer-2007 american society of clinical oncology/american society of hematology clinical practice guideline update. J Oncol Pract. 2010; 4(1):48-52. PMC: 2793924. DOI: 10.1200/JOP.0818502. View

15.

Palumbo A, Hajek R, Delforge M, Kropff M, Petrucci M, Catalano J . Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med. 2012; 366(19):1759-69. DOI: 10.1056/NEJMoa1112704. View

16.

Richardson P, Mitsiades C, Laubach J, Schlossman R, Ghobrial I, Hideshima T . Lenalidomide in multiple myeloma: an evidence-based review of its role in therapy. Core Evid. 2010; 4:215-45. PMC: 2899783. DOI: 10.2147/ce.s6002. View

17.

Harousseau J, Dimopoulos M, Wang M, Corso A, Chen C, Attal M . Better quality of response to lenalidomide plus dexamethasone is associated with improved clinical outcomes in patients with relapsed or refractory multiple myeloma. Haematologica. 2010; 95(10):1738-44. PMC: 2948100. DOI: 10.3324/haematol.2009.015917. View

18.

Knight R, Delap R, Zeldis J . Lenalidomide and venous thrombosis in multiple myeloma. N Engl J Med. 2006; 354(19):2079-80. DOI: 10.1056/NEJMc053530. View

19.

Biran N, Jacobus S, Vesole D, Callander N, Fonseca R, Williams M . Outcome with lenalidomide plus dexamethasone followed by early autologous stem cell transplantation in patients with newly diagnosed multiple myeloma on the ECOG-ACRIN E4A03 randomized clinical trial: long-term follow-up. Blood Cancer J. 2016; 6(9):e466. PMC: 5056965. DOI: 10.1038/bcj.2016.68. View

20.

Dimopoulos M, Spencer A, Attal M, Prince H, Harousseau J, Dmoszynska A . Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med. 2007; 357(21):2123-32. DOI: 10.1056/NEJMoa070594. View